FDA Application for Orphan Drug Designation , PAA, MPL, page-337

I have been doing a bit of research regarding big pharma drugs that are coming out of patent protection in the next 5 years. [Mainly on Bing AI so consider if you consider it reliable] There are some articles on Fierce pharma as well.

I started with Novartis, Sanofi and Biogen, between them they will be losing almost 20 Billion $US worth of sales that are currently protected by patents from 2027 to 2030. This is not to say they are in serious trouble as they all have pipelines etc. But I think its good for all on here to know what happens in the background, I had a great article that explained how important small bio companies are to big pharma as letting them do all the pre-clinical work and early trials saves them years and gives a broader spectrum to be involved in. I will try and find it.

So if Monepantel continues on the same trajectory, could it be ready by 2027 ? I think we all know the answer to that. But my main point is that it appears Monepantel will soon be right in the sweet spot.

Early Feb for the results "the graph" will hopefully get the attention of retail buyers but I think the important decisions and news may come between then and the start of the Phase 2/registration trial. Or maybe sooner to quote someone we all know.


Cheers